GHAPPcast: CD64+ Binding: Description, Relevance, and Potential Clinical Implications

Thank you to Johnson & Johnson for your support of this GHAPPcast episode.

In this insightful episode of GHAPPcast, the official podcast of the Gastroenterology and Hepatology Advanced Practice Providers, host Gabriella McCarty, NP-C, delves into the complex yet critical topic of CD64 positive binding and its relevance in inflammatory bowel disease (IBD) treatment, particularly in relation to Interleukin-23 (IL-23) inhibition. Gabriella is joined by Andrea Banty, NP, a respected GHAPP faculty member and expert in gastroenterology, who provides valuable insights into the role of CD64 in the immune system and its impact on diseases like Crohn’s disease and ulcerative colitis.

In this episode, Andrea explains how CD64 receptors, found on immune cells, are upregulated during inflammation and can contribute to IL-23 production. This protein plays a significant role in the pathogenesis of IBD and other inflammatory conditions. By targeting CD64 and inhibiting IL-23, therapies may reduce inflammation and promote healing in the GI mucosal lining, improving patient outcomes in ulcerative colitis and Crohn’s disease.

The podcast also discusses current therapies that target IL-23, including those that work at the P40 and P19 subunits, with an exciting focus on the potential of Guselkumab, a therapy that targets IL-23 at the P19 subunit and also binds CD64. This unique dual-action therapy has shown promise for the treatment of psoriasis and psoriatic arthritis and is anticipated to receive FDA approval for the treatment of IBD as well, offering a new avenue for advanced therapy.

As new therapeutic options emerge, Andrea and Gabriella explore the potential clinical applications of CD64 inhibition and IL-23 targeting, emphasizing the importance of personalized care in IBD management. The discussion highlights how advanced practice providers can make informed therapeutic decisions to improve IBD patient outcomes by considering factors such as efficacy, safety, and patient preferences for treatment routes.

This episode is a must-listen for gastroenterology professionals, advanced practice providers, and anyone interested in the evolving landscape of IBD treatment and immune modulation therapies. Visit the GHAPP website or download the GHAPP ACE app for more information.